(Q39136657)

9 September 2017

title

Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C. (English)

1 reference

9 September 2017

1 reference

1 reference

1 reference

Robert J Fontana

1

1 reference

9 September 2017

Linas A Bieliauskas

2

1 reference

9 September 2017

Karen L Lindsay

3

1 reference

9 September 2017

Carla Back-Madruga

4

1 reference

9 September 2017

Elizabeth C Wright

5

1 reference

9 September 2017

Kristin K Snow

6

1 reference

9 September 2017

Anna S F Lok

7

1 reference

9 September 2017

Ziad Kronfol

8

1 reference

9 September 2017

Latha Padmanabhan

9

1 reference

9 September 2017

HALT-C Trial Group

10

1 reference

9 September 2017

language of work or name

English

0 references

publication date

1 May 2007

1 reference

9 September 2017

1 reference

9 September 2017

volume

45

1 reference

9 September 2017

issue

5

1 reference

9 September 2017

page(s)

1154-1163

1 reference

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

9 September 2017

cites work

1 reference

Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia.

21 January 2018

1 reference

Persistent neurotoxicity of systemically administered interferon-alpha.

21 January 2018

1 reference

Neuropsychological effects of Interferon Alfa-n3 treatment in asymptomatic human immunodeficiency virus-1-infected individuals.

21 January 2018

1 reference

Neurological function during long-term therapy with recombinant interferon alpha

21 January 2018

1 reference

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

7 January 2021

Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment

1 reference

7 January 2021

Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice.

1 reference

7 January 2021

Side effects of therapy for chronic hepatitis C.

1 reference

7 January 2021

Neuropsychiatric toxicity of antiviral treatment in chronic hepatitis C.

1 reference

7 January 2021

Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C.

1 reference

7 January 2021

Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy

1 reference

7 January 2021

Cognitive function in hepatitis C patients with advanced fibrosis enrolled in the HALT-C trial

1 reference

7 January 2021

Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease

1 reference

7 January 2021

Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors.

1 reference

7 January 2021

Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders.

1 reference

7 January 2021

Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer.

1 reference

7 January 2021

Reliability and validity studies of the WHO--Composite International Diagnostic Interview (CIDI): a critical review

1 reference

7 January 2021

Reliability of alcohol use indices. The Lifetime Drinking History and the MAST

1 reference

7 January 2021

Clinical relevance of cognitive scores in hepatitis C patients with advanced fibrosis

1 reference

7 January 2021

1 reference

7 January 2021

Paroxetine for the prevention of depression induced by high-dose interferon alfa

1 reference

7 January 2021

Prefrontal cortical hypometabolism during low-dose interferon alpha treatment.

1 reference

7 January 2021

1 reference

7 January 2021

Neurotoxicity of interferon-alpha in melanoma therapy: results from a randomized controlled trial

1 reference

7 January 2021

Mood, cognition and EEG changes during interferon alpha (alpha-IFN) treatment for chronic hepatitis C.

1 reference

7 January 2021

Effect of interferon-alpha on cognitive functioning in patients with chronic hepatitis C

1 reference

7 January 2021

The effects of practice on the cognitive test performance of neurologically normal individuals assessed at brief test-retest intervals.

1 reference

7 January 2021

Practice effect and test-retest reliability of attentional and executive tests in middle-aged to elderly subjects.

1 reference

7 January 2021

Selective reminding test: an examination of the equivalence of four forms.

1 reference

7 January 2021

Practice effects on commonly used measures of executive function across twelve months

1 reference

7 January 2021

Neuropsychological practice effects and change detection in people with schizophrenia.

1 reference

7 January 2021

Circadian preference and cognitive functioning among rehabilitation inpatients.

1 reference

7 January 2021

Depression, anemia and health-related quality of life in chronic hepatitis C.

1 reference

7 January 2021

Reliable screening for neuropsychological impairment in multiple sclerosis

1 reference

7 January 2021

Metamemory in multiple sclerosis: exploring affective and executive contributors.

1 reference

7 January 2021

The relationship between memory performance, perceived cognitive function, and mood in patients with epilepsy.

1 reference

7 January 2021

Self-report of cognitive abilities in temporal lobe epilepsy: cognitive, psychosocial, and emotional factors.

1 reference

7 January 2021

Evidence for a cerebral effect of the hepatitis C virus

1 reference

7 January 2021

Search for hepatitis C virus negative-strand RNA sequences and analysis of viral sequences in the central nervous system: evidence of replication

1 reference

7 January 2021

Effect of interferon-beta-1b on cognitive functions in multiple sclerosis.

1 reference

7 January 2021

Monoaminergic neurotransmission is altered in hepatitis C virus infected patients with chronic fatigue and cognitive impairment

1 reference

7 January 2021

IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.21633

1 reference

9 September 2017

1 reference